好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque Brain
Child Neurology and Developmental Neurology
P5 - Poster Session 5 (5:30 PM-6:30 PM)
7-065

To determine whether caffeine augments isoflurane neurotoxicity in the fetal macaque brain.

Caffeine is one of the most frequently used medications in premature infants. It is the respiratory stimulant of choice for apnea associated with prematurity and has been called the silver bullet in neonatology because of many proven benefits and few known risks. Research has revealed that sedative/anesthetic drugs trigger apoptotic death of neurons and oligodendrocytes in developing mammalian brains. Here we evaluated the influence of caffeine on the neurotoxicity of anesthesia in developing nonhuman primate brains.

Fetal macaques (n = 7–8/group), at a neurodevelopmental age comparable to premature human infants, were exposed in utero for 5 hours to no drug (control), isoflurane, or isoflurane + caffeine and examined for evidence of apoptosis.

Isoflurane exposure increased apoptosis 3.3 fold for neurons and 3.4 fold for oligodendrocytes compared to control brains. Isoflurane + caffeine caused neuronal apoptosis to increase 8.0 fold compared to control levels but did not augment oligoapoptosis. Neuronal death was particularly pronounced in the basal ganglia and cerebellum. Higher blood levels of caffeine within the range considered therapeutic and safe for human infants correlated with increased neuroapoptosis but not oligoapoptosis.

Caffeine markedly augments isoflurane neurotoxicity in the fetal macaque brain and challenges the assumption that caffeine is completely safe for use in conjunction with sedative and anesthetic drugs in premature human infants.

Authors/Disclosures

PRESENTER
No disclosure on file
Stephen A. Johnson, MD (Mayo Clinic) The institution of Dr. Johnson has received research support from ALS Association.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Hrissanthi Ikonomidou, MD, PhD (University of Wisconsin, Child Neurology) An immediate family member of Dr. Ikonomidou has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for RNN Journal. An immediate family member of Dr. Ikonomidou has stock in Solvay. Dr. Ikonomidou has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with NIH, FDA.
No disclosure on file
No disclosure on file
No disclosure on file